Business, energy, technology, markets and global industry news from Business News Today

Trop2 ADC

PharmaDeviceNews Trop2 ADC
Representative image of a lung cancer treatment setting, as OptiTROP-Lung05 data put sacituzumab tirumotecan at the centre of the first-line NSCLC immunotherapy debate.
Pharma & Biotech

Can TROP2 ADCs reshape first-line NSCLC after Kelun-Biotech’s OptiTROP-Lung05 win?

A TROP2 ADC just pushed past pembrolizumab alone in first-line lung cancer. See why OptiTROP-Lung05 matters now.

Read More
Representative image: Advanced lung cancer research and oncology treatment planning are becoming central to the debate over whether Kelun-Biotech’s sacituzumab tirumotecan and pembrolizumab combination can reshape first-line NSCLC care.
Pharma & Biotech

Why Kelun-Biotech’s sac-TMT review could reshape China’s lung cancer ADC market

ADC ambition meets Keytruda dominance. Kelun-Biotech’s sac-TMT filing could test how far TROP2 combinations can move in lung cancer.

Read More
Pharma & Biotech

Can Biohaven’s BHV-1510 avoid the safety pitfalls of existing Trop2 ADCs in solid tumors?

Biohaven Ltd. presented updated Phase 1 clinical data on BHV-1510, its next-generation Trop2-targeting antibody-drug conjugate, at the 2025 European Society for Medical Oncology (ESMO) Immuno-Oncology Congress in London. The results, derived from a heavily pretreated population with advanced or metastatic solid tumors, showed encouraging response rates across non-small cell lung cancer, endometrial cancer, and urothelial

Read More